Literature DB >> 2772705

Determination of quinine and quinidine in biological fluids by high performance liquid chromatography.

J Karbwang1, K Na Bangchang, P Molunto, D Bunnag.   

Abstract

A simple, specific, rapid and sensitive High Performance Liquid Chromatography (HPLC) method has been developed to measure plasma level of quinine and quinidine. The drugs were extracted successively from plasma at basic pH with chloroform and quantified on a revers-phase Z-module C18 HPLC column with fluorescence detector (excitation 340 nm, emission 425 nm). The isocratic mobile phase used was the mixture of 0.05 M ammonium formate and acetonitrile (93.5:6.5, v/v), adjusted pH to 2.0 with ortho-phosphoric acid. The limits of quantitation for these compounds were as low as 4 ng/ml of plasma, using a 0.25 ml specimen. Calibration curves were linear (R squared = 0.9994) in the range 0-7,000 ng/ml. An interassay reproducibility was 6.8%, 0.3% and 1.2% at the concentrations of 250 ng, 4,000 ng and 8,000 ng of quinine, respectively. Inter-assay coefficient of variation of quinidine was 1.8%, 2.7% and 3.7% at the concentrations of 250 ng, 1,500 ng and 3,000 ng, respectively. Recovery of quinine and quinidine were 76% and 81%, respectively. The method has been used in the analysis of quinine and quinidine in healthy volunteers receiving quinine or quinidine intravenously. The method is now being used to assay samples from field studies with satisfactory results.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2772705

Source DB:  PubMed          Journal:  Southeast Asian J Trop Med Public Health        ISSN: 0125-1562            Impact factor:   0.267


  10 in total

1.  Pharmacokinetics of quinine in patients with chronic renal failure.

Authors:  P Rimchala; J Karbwang; K Sukontason; V Banmairuroi; P Molunto; K Na-Bangchang
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

2.  Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.

Authors:  T M Davis; J Karbwang; S Looareesuwan; R C Turner; N J White
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

3.  A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males.

Authors:  J Karbwang; T M Davis; S Looareesuwan; P Molunto; D Bunnag; N J White
Journal:  Br J Clin Pharmacol       Date:  1993-03       Impact factor: 4.335

4.  The pharmacokinetics of quinine in patients with hepatitis.

Authors:  J Karbwang; A Thanavibul; P Molunto; K Na Bangchang
Journal:  Br J Clin Pharmacol       Date:  1993-04       Impact factor: 4.335

5.  Absence of significant pharmacokinetic and pharmacodynamic interactions between artemether and quinoline antimalarials.

Authors:  K Na-Bangchang; J Karbwang; R Ubalee; A Thanavibul; S Saenglertsilapachai
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Jul-Dec       Impact factor: 2.441

6.  Pharmacokinetics of quinine in chronic liver disease.

Authors:  P Auprayoon; K Sukontason; K Na-Bangchang; V Banmairuroi; P Molunto; J Karbwang
Journal:  Br J Clin Pharmacol       Date:  1995-11       Impact factor: 4.335

7.  Effects of sex on the pharmacokinetic and pharmacodynamic properties of quinidine.

Authors:  Hala El-Eraky; Simon H L Thomas
Journal:  Br J Clin Pharmacol       Date:  2003-08       Impact factor: 4.335

8.  Pharmacokinetic Interactions Between Quinine and Lopinavir/Ritonavir in Healthy Thai Adults.

Authors:  Siwalee Rattanapunya; Tim R Cressey; Ronnatrai Rueangweerayut; Yardpiroon Tawon; Panida Kongjam; Kesara Na-Bangchang
Journal:  Am J Trop Med Hyg       Date:  2015-09-28       Impact factor: 2.345

9.  Pharmacokinetics of oral artesunate in thai patients with uncomplicated falciparum malaria.

Authors:  J Karbwang; K Na-Bangchang; K Congpoung; A Thanavibul; T Harinasuta
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

10.  Abnormal circulatory control in falciparum malaria: the effects of antimalarial drugs.

Authors:  W Supanaranond; T M Davis; S Pukrittayakamee; B Nagachinta; N J White
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.